Altimmune, Inc.
ALT
$7.03
$0.253.69%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.00% | 0.00% | |||
| Cost of Revenue | -19.99% | -0.11% | |||
| Gross Profit | 19.99% | 0.11% | |||
| SG&A Expenses | 17.74% | 2.44% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.27% | 0.40% | |||
| Operating Income | 12.27% | -0.40% | |||
| Income Before Tax | 12.61% | -1.47% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 15.55% | -1.47% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 15.55% | -1.47% | |||
| EBIT | 12.27% | -0.40% | |||
| EBITDA | 12.27% | -0.42% | |||
| EPS Basic | 20.35% | -1.21% | |||
| Normalized Basic EPS | 17.56% | -1.19% | |||
| EPS Diluted | 20.35% | -1.21% | |||
| Normalized Diluted EPS | 17.56% | -1.19% | |||
| Average Basic Shares Outstanding | 6.02% | 0.25% | |||
| Average Diluted Shares Outstanding | 6.02% | 0.25% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||